e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease
Fajac I., Viel M., Gaitch N., Hubert D., Bienvenu T.
Source:
Eur Respir J 2009; 34: 772
Journal Issue:
September
Disease area:
Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Fajac I., Viel M., Gaitch N., Hubert D., Bienvenu T.. Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease. Eur Respir J 2009; 34: 772
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Targeting CFTR as a therapy for cystic fibrosis
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two
F508del
alleles
Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019
Year: 2019
Potentiating and correcting mutant CFTR in patients with cystic fibrosis
Source: Eur Respir Monogr 2014; 64: 129-149
Year: 2014
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis
Source: Eur Respir Rev 2013; 22: 58-65
Year: 2013
Nasal potential difference of carriers of the W493R ENaC variant with non-cystic fibrosis bronchiectasis
Source: Eur Respir J 2016; 47: 322-324
Year: 2016
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation
Source: Eur Respir Rev 2013; 22: 66-71
Year: 2013
CFTR: cystic fibrosis and beyond
Source: Eur Respir J 2014; 44: 1042-1054
Year: 2014
CFTR gene mutations detected in Japanese individuals with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 716s
Year: 2006
Distinctive CFTR gene mutations found in Japanese individuals with cystic fibrosis
Source: Annual Congress 2004 - Cystic fibrosis in the 21
st
century: cutting edge investigations, taxing problems
Year: 2004
A novel
CFTR
mutation found in a Chinese cystic fibrosis patient
Source: Eur Respir J 2005; 26: Suppl. 49, 402s
Year: 2005
Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients
Source: Eur Respir J 2004; 23: 679-684
Year: 2004
Atypical cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38
Year: 2006
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019
Year: 2020
Analysis of CFTR gene mutations in 24 Japanese individuals with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
First identified “severe” mutations and extended rearrangements in the CFTR gene in Russian cystic fibrosis patients
Source: Virtual Congress 2020 – Cystic fibrosis
Year: 2020
Oral contraceptives do not appear to affect cystic fibrosis disease severity
Source: Eur Respir J 2013; 41: 67-73
Year: 2013
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept